JP2016517884A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517884A5
JP2016517884A5 JP2016511726A JP2016511726A JP2016517884A5 JP 2016517884 A5 JP2016517884 A5 JP 2016517884A5 JP 2016511726 A JP2016511726 A JP 2016511726A JP 2016511726 A JP2016511726 A JP 2016511726A JP 2016517884 A5 JP2016517884 A5 JP 2016517884A5
Authority
JP
Japan
Prior art keywords
composition
disease
condition
composition according
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016511726A
Other languages
English (en)
Japanese (ja)
Other versions
JP6360552B6 (ja
JP6360552B2 (ja
JP2016517884A (ja
Filing date
Publication date
Priority claimed from PCT/US2013/053640 external-priority patent/WO2014178892A1/en
Application filed filed Critical
Publication of JP2016517884A publication Critical patent/JP2016517884A/ja
Publication of JP2016517884A5 publication Critical patent/JP2016517884A5/ja
Application granted granted Critical
Publication of JP6360552B2 publication Critical patent/JP6360552B2/ja
Publication of JP6360552B6 publication Critical patent/JP6360552B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016511726A 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム Active JP6360552B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
USPCT/US2013/0053640 2013-08-05
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018118891A Division JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム

Publications (4)

Publication Number Publication Date
JP2016517884A JP2016517884A (ja) 2016-06-20
JP2016517884A5 true JP2016517884A5 (cg-RX-API-DMAC7.html) 2017-03-09
JP6360552B2 JP6360552B2 (ja) 2018-07-18
JP6360552B6 JP6360552B6 (ja) 2018-08-15

Family

ID=51843844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016511718A Withdrawn JP2016517883A (ja) 2013-05-03 2013-08-05 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2016511726A Active JP6360552B6 (ja) 2013-05-03 2014-02-05 髄鞘形成疾患の処置におけるソベチロム
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016511718A Withdrawn JP2016517883A (ja) 2013-05-03 2013-08-05 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018118891A Pending JP2018141024A (ja) 2013-05-03 2018-06-22 髄鞘形成疾患の処置におけるソベチロム
JP2018137754A Pending JP2018162321A (ja) 2013-05-03 2018-07-23 X連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Country Status (12)

Country Link
US (3) US10226438B2 (cg-RX-API-DMAC7.html)
EP (1) EP2991670B8 (cg-RX-API-DMAC7.html)
JP (4) JP2016517883A (cg-RX-API-DMAC7.html)
CN (1) CN105431163A (cg-RX-API-DMAC7.html)
AU (1) AU2014260468A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015027682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2911309A1 (cg-RX-API-DMAC7.html)
ES (1) ES2745532T3 (cg-RX-API-DMAC7.html)
MX (2) MX379043B (cg-RX-API-DMAC7.html)
RU (1) RU2015151216A (cg-RX-API-DMAC7.html)
SG (2) SG10201709090UA (cg-RX-API-DMAC7.html)
WO (2) WO2014178892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) * 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
CN109641003A (zh) * 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
EP3644983B1 (en) 2017-06-29 2023-10-25 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
JP2002519340A (ja) 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
CA2583410A1 (en) * 2004-09-15 2006-03-23 Albany College Of Pharmacy Thyroid hormone analogs for promoting angiogenesis
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) * 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Similar Documents

Publication Publication Date Title
RU2015151216A (ru) Собетиром для лечения заболеваний, связанных с миелинизацией
Hagerman et al. The fragile X family of disorders: a model for autism and targeted treatments
Crespel et al. Management of juvenile myoclonic epilepsy
Jang et al. Viral parkinsonism
Qiu et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica
JP2021080269A5 (cg-RX-API-DMAC7.html)
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
JP2018531965A5 (cg-RX-API-DMAC7.html)
Wang et al. Adolescent microglia stimulation produces long-lasting protection against chronic stress-induced behavioral abnormalities in adult male mice
Alme et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
Tan et al. Pharmacological therapies for Angelman syndrome
FI3634396T3 (fi) Koostumus L-DOPA-hoidon tehon parantamiseen
Zhang et al. Excitatory amino acid transporters as therapeutic targets in the treatment of neurological disorders: their roles and therapeutic prospects
Gautier et al. Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease
Sienaert et al. Adult catatonia: etiopathogenesis, diagnosis and treatment
JP2015508824A5 (cg-RX-API-DMAC7.html)
Juhi et al. Ataxia, Manifestation of Phenytoin Toxicity: A Case Report.
Duggal Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder
Caykoylu et al. Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy
US20090099259A1 (en) Method for regulating gene expression
JP2020527132A5 (cg-RX-API-DMAC7.html)
Chaves et al. The role of inflammation in schizophrenia: an overview
Sookaromdee et al. Adverse Effects of Telemedicine